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Abstract
Osteoarthritis (OA) is a major cause of pain and physical disability in adults, and an increasingly common disease given its 
associations with aging and a growing obese/overweight population. Paracetamol is widely recommended for analgesia at an 
early stage in the management of OA, and, although frequently prescribed, evidence suggests the efficacy of paracetamol for 
OA pain is low. Furthermore, there have been recent concerns over the safety profile of paracetamol, with reports of gastroin-
testinal, cardiovascular, hepatic and renal adverse events. This narrative review summarizes recent literature on the benefits and 
harms of paracetamol for OA pain. Data on long-term paracetamol safety are derived largely from observational evidence, and 
are difficult to interpret given the potential biases of such data. Nonetheless, a considerable degree of toxicity is associated with 
paracetamol use among the general population, especially at the upper end of standard analgesic doses. Paracetamol is linked 
to liver function abnormalities and there is evidence for liver failure associated with non-intentional paracetamol overdose. 
Safety data for paracetamol use in the older population (aged >65 years) are sparse; however, there is some evidence that frail 
elderly people may have impaired paracetamol clearance. Given that the analgesic benefit of paracetamol in OA joint pain is 
uncertain and potential safety issues have been raised, more careful consideration of its use is required.
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1 Introduction
Osteoarthritis (OA) is a major cause of pain in adults [1]. 
Pain associated with OA of the hip and knee results in 
increased physical and walking disability, which increases 
the risk of all-cause mortality [2]. OA is an increasingly 
common disease given its associations with aging and a 
growing obese/overweight population, with symptomatic 
knee OA affecting more than 250 million older people (>50 
years) worldwide [3]. Paracetamol (acetaminophen), discov-
ered over 140 years ago, is still one of the most commonly 
used analgesic and antipyretic medications across the world, 
and is included on the World Health Organization’s List of 
Essential Medicines, the most effective and safe medicines 
needed in a health system [4, 5]. The management of pain 
in OA is based on a combination of pharmacologic and non-
pharmacologic approaches, with paracetamol commonly 
recommended for analgesia at an early step in treatment 
recommendations [6–9]. Use is often driven by an absence 
of therapeutic alternatives, especially given the safety pro-
file of non-steroidal anti-inflammatory drugs (NSAIDs) and 
opioids. Each year in the US, approximately 6% of adults 
are prescribed paracetamol doses of more than 4 g/day, 
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Key Points 
Paracetamol is widely used for analgesia in osteoarthritis 
despite reported low efficacy, with use largely driven by 
a lack of effective or tolerated alternative treatments, and 
its relative safety.
However, there is some evidence demonstrating gastro-
intestinal, cardiovascular, hepatic and renal toxicity with 
paracetamol, perhaps reflecting populations that use this 
drug, but requiring further investigation.
Although paracetamol remains safer than some alterna-
tive therapies, such as non-steroidal anti-inflammatory 
drugs, paracetamol should be used carefully, particularly 
for chronic pain management.
used both. The prescription of paracetamol was variable, 
ranging from 0% in Germany up to 6% in Spain, while the 
use of prescription NSAIDs was highest in Germany (82%) 
and lowest in France (47%). However, OTC medication use 
was reported by 15–30% of people [14], and paracetamol 
was likely included in this OTC use. Variation in the use of 
pharmacotherapy for OA between countries may be driven 
by national prescribing guidelines and health system eco-
nomics (for example, in countries where costs of medical 
consultation and prescription outweigh the OTC price for 
paracetamol, prescription may be low). Of the prescription 
medications, respondents had been using paracetamol for 
the longest duration (mean 84 months) and for 21 days of 
the last month [14]. A prospective cohort study of analgesic 
prescribing to older people (aged > 75 years; N = 149) by 
general practitioners in France found that pain was largely 
due to OA, and, among those receiving at least one analgesic 
(66%), almost all received paracetamol (> 96%), which is in 
line with national prescribing guidance [15].
Despite the availability of analgesics, inadequate pain 
relief is common among patients with knee OA and is asso-
ciated with large functional loss and impaired quality of life. 
In an observational study of real-world therapies for OA, 
after ≥ 2 weeks of physician-prescribed treatment, more 
than half of patients with knee OA reported inadequate pain 
relief defined as moderate to severe pain [16]. The most 
commonly prescribed analgesic medications were NSAIDs 
(60% of patients), followed by paracetamol (44%) and opi-
oid-containing medications (27%).
Chronic multiple-site joint pain (MSJP) is common in 
older people and is associated with poor outcomes. MSJP 
represents a combination of OA, back pain and soft tissue 
disorders; muscle weakness is extremely common [17]. In 
a cohort of MSJP patients, concurrent pharmacological 
therapies were used by 47%. Paracetamol was used by 62% 
of patients (38% on prescription) and 23% regularly used 
paracetamol. Among the 26% of MSJP patients who had 
previously stopped taking paracetamol, 98% reported stop-
ping due to inefficacy or a loss of efficacy [17].
3  Paracetamol Efficacy in OA
Although widely used as a first-line analgesic in OA, there 
are increasing doubts, from recent meta-analyses, regarding 
the analgesic efficacy of paracetamol. A Cochrane review 
on paracetamol in OA, performed over a decade ago, found 
a significantly superior reduction in pain compared with 
placebo from seven RCTs, albeit with a small effect size 
(ES; standardized mean difference [SMD] − 0.14, 95% con-
fidence interval [CI] − 0.23 to − 0.05) [18]. In a subsequent 
analysis adjusting for trial quality, when the five high-qual-
ity, placebo-controlled RCTs were considered in isolation 
and 30,000 patients are hospitalized for paracetamol toxic-
ity [10]. Although traditionally considered safe, in recent 
years, a steady increase in the number of registered cases 
of paracetamol-induced liver toxicity has been observed 
worldwide [4]. Although older patients are among the high-
est users of analgesic medications for musculoskeletal pain, 
there is limited clinical evidence to inform on the safe and 
effective use of these medications in the elderly population 
[11]. A review of 83 clinical trials involving >10,000 sub-
jects treated with simple analgesics found that only 2.3% of 
people were aged over 65 years [12]. This narrative litera-
ture review aims to describe the use, efficacy and toxicity 
associated with chronic use of paracetamol for OA pain. 
Given the paucity of long-term randomized controlled trials 
(RCTs), safety data from observational, cohort studies were 
also considered.
2  The Use of Paracetamol in Osteoarthritis 
(OA)
Paracetamol is frequently prescribed for analgesia. Among 
participants in the USA Osteoarthritis Initiative (OAI), 
over 80% reported using medication for knee pain in the 
previous 12 months, and 70% had used a conventional 
analgesic or nutraceutical for more than half of the days 
of the month, of which paracetamol was taken by 14% of 
participants [13]. The 2011 National Health and Wellness 
Survey (NHWS) collected information on 57,512 adults 
(aged ≥ 18 years) from the general population of five EU 
countries. Among people with self-reported peripheral joint 
OA (n = 3750; mostly aged 55–74 years), nearly half (47%) 
reported prescription medication use, 27% reported use of 
over-the-counter (OTC) medications, and 9% of patients 
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(Jadad score = 5), the ES of paracetamol on pain was even 
smaller (ES 0.10, 95% CI − 0.03 to 0.23) [19]. This analysis 
also suggested that paracetamol had no significant effect on 
stiffness (ES 0.16, 95% CI − 0.05 to 0.37) or physical func-
tion (ES 0.09, 95% CI − 0.03 to 0.22) [19].
In a recent systematic review and meta-analysis, paraceta-
mol was found to provide minimal short-term benefit for peo-
ple with OA [20]. For hip or knee OA, there was ‘high quality’ 
evidence that paracetamol provided a significant, although not 
clinically important, effect on pain (weighted mean difference 
[WMD] − 3.7, 95% CI − 5.5 to − 1.9) and disability (WMD 
− 2.9, 95% CI − 4.9 to − 0.9) in the short term (> 2 weeks 
and ≤ 3 months). In the immediate term (≤ 2 weeks), the 
effect of paracetamol on pain was lower (WMD − 3.3, 95% CI 
− 5.8 to − 0.8), with no immediate effect on function (WMD 
− 1.7, 95% CI − 6.0 to 2.6). In a 2017 network meta-analysis 
of analgesic medications for the management of pain in knee 
and hip OA, the authors concluded, on the basis of the avail-
able data, that there is no role for single-agent paracetamol in 
the treatment of OA patients irrespective of dose [21].
A recent meta-analysis focusing on the long-term effi-
cacy of pharmacotherapy for OA [22], identified only one 
RCT of > 12 months’ duration that included paracetamol 
(650 mg, four times daily) in comparison with naproxen 
(375 mg, twice daily) [23]. The study found similar efficacy 
between paracetamol and naproxen among patients who 
completed the 2-year study (n = 27/88 with paracetamol 
and n = 35/90 with naproxen), although a very high with-
drawal rate was observed. Withdrawal due to lack of drug 
efficacy was more frequent for paracetamol (22%) compared 
with naproxen (16%), with withdrawal due to adverse drug 
reactions common in both groups, although slightly higher 
for the NSAID (18% with paracetamol and 23% with nap-
roxen) [23].
4  Paracetamol Safety
Paracetamol is generally considered to be safer than other 
commonly used analgesics such as NSAIDs or opiates. How-
ever, a recent systematic literature review of observational 
studies (given an absence of long-term trials) reported a con-
siderable degree of toxicity associated with paracetamol use 
among the general adult population, especially at the upper 
end of standard analgesic doses [24]. A striking trend of 
dose-response was observed between paracetamol at stand-
ard analgesic doses and adverse events (AEs) that are often 
observed with NSAIDs, including an increasing incidence 
of mortality, cardiovascular, gastrointestinal (GI) and renal 
AEs in the general population. Eight cohort studies met the 
inclusion criteria and investigated one or more of the AEs 
of interest, with oral doses of paracetamol 0.5–1.0 g every 
4–6 h to a maximum of 4.0 g/day [24]. Two of the studies 
included in this analysis reported on mortality, of which one 
reported a dose–response increase in all-cause mortality and 
rate of GI AEs or bleeds based on the low to high medication 
possession ratio (measured by repeat prescription frequency) 
(Table 1) [25]. The other study reported an increase in stand-
ardized mortality ratio for patients prescribed paracetamol 
compared with those not prescribed paracetamol, regardless 
of the specific cause of death, with a nearly doubled overall 
death rate [26]. Four studies included in the meta-analysis 
showed a dose–response relationship with risk of cardiovas-
cular AEs. One study reported an increasing risk ratio of all 
cardiovascular AEs based on dosing frequency (Table 1), 
and three studies included in the meta-analysis reported 
on the risk of renal AEs with paracetamol, with one study 
reporting a dose-ranging increase in odds ratio (OR) based 
on cumulative intake and measured as a ≥ 30% decrease in 
estimated glomerular filtration rate (eGFR), ranging from 
1.80 with up to 500 g in a lifetime (95% CI 1.02–3.18) to 
2.04 with > 3000 g (95% CI 1.28–3.25) [27].
4.1  Cardiovascular/Cerebrovascular Adverse Events 
(AEs)
4.1.1  Hypertension
Concomitant paracetamol can adversely affect the efficacy 
of antihypertensive therapy (with ramipril or valsartan) [28]. 
In a double-blind crossover trial, 174 hypertensive patients 
with OA were treated with antihypertensives for 8 weeks. 
Of those patients, 135 with normalized blood pressure were 
randomized to naproxen or paracetamol for 2 weeks. Nap-
roxen significantly increased clinic and ambulatory systolic/
diastolic blood pressure in patients treated with ramipril or 
valsartan (p < 0.05), but not aliskiren. Paracetamol slightly 
but significantly affected clinic and ambulatory blood pres-
sure in all three groups and also produced a small but sig-
nificant increase in heart rate (p < 0.05).
This study cannot account for individual pain over the 
study period, and pain can drive hypertension. Nevertheless, 
when paracetamol is chosen for OA management in subjects 
with hypertension, patients should be evaluated as carefully 
as when traditional NSAIDs are administered.
4.1.2  Acute Myocardial Infarction
The risk of non-fatal acute myocardial infarction (AMI) 
associated with traditional NSAIDs, non-narcotic anal-
gesics (paracetamol and metamizole), and symptomatic 
slow-acting drugs in OA (SYSADOAs) was assessed in a 
Spanish primary care database study of case-control design 
(cases = 3833, controls = 20,000) [29]. The greatest risk of 
non-fatal AMI occurred with high background cardiovascu-
lar risk patients and long use of traditional NSAIDs (> 365 
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days) (OR 1.80, 95% CI 1.26–2.58). Paracetamol (OR 0.84, 
95% CI 0.74–0.95), glucosamine and chondroitin (OR 0.68, 
95% CI 0.47–0.99) were not associated with increased risk.
4.1.3  Stroke
The risk of non-fatal ischaemic stroke associated with 
NSAIDs and paracetamol was assessed in a Spanish 
population-based, case-control study (cases = 2888, con-
trols = 20,000) [30]. No increased risk was found with par-
acetamol (OR 0.97, 95% CI 0.85–1.10) or glucosamine and 
chondroitin (OR 0.94, 95% CI 0.67–1.33), and no increased 
risk was observed with traditional NSAIDs as a group 
(OR 1.03, 95% CI 0.90–1.19). Not surprisingly, there was an 
increased risk with diclofenac (OR 1.53; 95% CI 1.19–1.97), 
especially with high doses over long-term periods (>365 
days) and in patients with high background cardiovascular 
risk.
4.2  Gastrointestinal (GI) AEs
In the past, paracetamol was considered to be without GI 
toxicity, however some studies suggest an increase in GI 
AE rates with paracetamol use. Two RCTs found the overall 
rate of GI AEs (most commonly nausea, abdominal pain and 
dyspepsia) with paracetamol to be similar to that found with 
ibuprofen, i.e. 9% and 13%, respectively [31], and 13% and 
12%, respectively [32, 33]. Using patient data from the UK 
General Practice Research Database (GPRD), an associa-
tion between paracetamol use and risk of symptomatic ulcer 
has been found versus non-use (relative risk 1.9, 95% CI 
1.5–2.3) [34]. A nested case-control study from the UK pop-
ulation compared analgesic use in 2105 cases of upper GI 
bleeding/perforations versus 11,500 age- and sex-matched 
controls (aged 40–79 years) and found an elevated risk of 
upper GI complications with paracetamol compared with 
controls (relative risk [RR] 1.3, 95% CI 1.1–1.5), which 
increased to more than threefold elevated risk among those 
talking paracetamol at doses >2 g/day (RR 3.6, 95% CI 
2.6–5.1) [35].
4.2.1  GI Hospitalization
The rates of hospitalization for GI disorders (ulceration, per-
foration, or bleeding in the upper or lower GI tract) among 
elderly patients (≥ 65 years) taking traditional NSAIDs, or 
the combination of a traditional NSAID and paracetamol 
with and without a proton pump inhibitor (PPI) versus those 
taking paracetamol alone, were assessed among a Canadian 
population-based retrospective cohort study [36]. The study 
found that for elderly patients requiring analgesic/anti-inflam-
matory treatment, use of the combination of a traditional 
NSAID and paracetamol may increase the risk of GI bleed-
ing compared with either agent alone. Among the cohort of 
644,183 elderly patients, there were 1854 GI hospitalizations. 
The rate of GI hospitalization was twice as high when an 
NSAID and paracetamol were used together (with or without 
a PPI) (Table 2). Patients with OA or rheumatoid arthritis 
diagnoses (n = 115,305, 18% of cohort) had a higher risk 
of GI events with paracetamol > 3 g/day compared with the 
main cohort (hazard ratio [HR] 1.42, 95% CI 1.04–1.93).
4.3  Severe Acute Liver Injury
Paracetamol is a dose-dependent hepatotoxin, and exces-
sive doses may lead to irreversible acute liver failure [37]. 
Glucuronidation and sulfation are the major metabolic path-
ways (phase II) for paracetamol metabolism, which become 
Table 1  Increased risk of adverse outcomes with frequent paracetamol dosing
Data compiled from Roberts et al. [24]
AEs adverse events, CI confidence interval, IV instrumental variables, MPR medication possession ratio (based on repeat prescription fre-
quency), PCM paracetamol, RR relative risk
a The RR (IV, fixed) of all-cause mortality in patients taking paracetamol versus patients not taking paracetamol
b The RR (IV, fixed) of upper gastrointestinal AEs (gastroduodenal ulcers, and complications such as upper gastrointestinal haemorrhages) in 
patients taking paracetamol versus patients not taking paracetamol
c The risk ratio (IV, fixed) of cardiovascular AEs (confirmed or probable non-fatal myocardial infarction, non-fatal stroke, fatal coronary heart 
disease or fatal stroke) in patients taking paracetamol versus patients not taking paracetamol
Adverse outcomes Repeat use, low MPR Repeat use, medium MPR Repeat use, high MPR Repeat use, very high MPR
All-cause  mortalitya [RR (95% CI)] 
[25]
0.95 (0.92–0.98) 1.08 (1.05–1.11) 1.27 (1.21–1.33) 1.63 (1.58–1.68)
Gastrointestinal  AEsb [RR (95% CI)] 
[25]
1.11 (1.04–1.18) 1.25 (1.12–1.40) 1.49 (1.29–1.72) 1.49 (1.34–1.66)
PCM 1 day/week PCM 2–3 days/week PCM 4–5 days/week PCM 6–7 days/week
Cardiovascular  AEsc [risk ratio 
(95% CI)] [42]
0.94 (0.62–1.43) 1.23 (0.94–1.61) 1.49 (0.99–2.24) 1.50 (1.10–2.05)
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saturated after paracetamol overdose, causing a shift to 
phase I metabolism and formation of a toxic metabolite that 
depletes glutathione and triggers mitochondrial dysfunction, 
resulting in cellular necrosis [38]. A number of studies have 
investigated the pharmacokinetics of paracetamol in healthy 
older adults, reporting variable effects of age [11]. General 
health state appears to have a greater effect on paracetamol 
clearance than age. Although preserved in healthy older 
adults, clearance to paracetamol glucuronide was markedly 
reduced in frail elderly patients when compared with fit sub-
jects [39].
Three trials have evaluated the results of liver function 
tests to detect AEs with paracetamol (alanine aminotrans-
ferase [ALT] and/or aspartate aminotransferase [AST]) in 
participants with OA, where an abnormal test was defined 
as hepatic enzyme activity 1.5 times the upper limit of nor-
mal. Participants taking paracetamol in the management of 
spinal pain and OA of the hip or knee were nearly four-
fold more likely to have abnormal results on liver function 
tests than participants taking placebo (WMD 3.8, 95% CI 
1.9–7.4) [20].
Acute drug overdose with paracetamol may cause acute 
liver failure leading to transplantation (ALFT). Overdose 
ALFT in Europe was evaluated in the Study of Acute Liver 
Transplantation (SALT) [40]. Overall, 600 cases of ALFT 
were identified in 52 transplant centres, of which paraceta-
mol overdose, even without suicidal intent, was responsible 
for 20% of cases. Among 301 ALFT cases without clinical 
aetiology, 81 (27%) were exposed to paracetamol but with-
out overdose in the prior 30 days. When non-overdose par-
acetamol-associated ALFTs were considered, the event rates 
were very similar, between 2.6 and 4.1 (mean 3.3) cases per 
million treatment-years of paracetamol sold (Table 3), with 
no difference between countries.
Paracetamol poisoning is the major cause of severe acute 
hepatotoxicity in the UK. In a single-centre cohort study 
from the Scottish Liver Transplantation Unit, the clini-
cal impact of staggered overdoses and delayed presenta-
tion following paracetamol overdose were examined [41]. 
The study found that ‘staggered’ paracetamol overdoses 
(repeated supratherapeutic ingestions of paracetamol), fre-
quently taken to relieve pain, are strongly associated with 
reduced survival compared with single time-point overdose 
[41]. From the 938 cases of severe acute liver injury admit-
ted over a period of 16 years (1992–2008), 663 (70.7%) 
were due to paracetamol-induced hepatotoxicity, and 161 
(24.3%) had taken a ‘staggered’ paracetamol overdose com-
pared with a single time-point overdose. Staggered overdose 
pattern was associated with older age and chronic alcohol 
abuse (a potential enhancer of paracetamol hepatotoxicity), 
resulting in worse clinical outcomes than single time-point 
paracetamol overdose. Relief of pain (58.2%) was the most 
common rationale for repeated supratherapeutic ingestion, 
and musculoskeletal pain was the third most common reason 
for staggered overdose (14.3%). Despite lower total ingested 
paracetamol doses and lower admission serum ALT, stag-
gered overdose patients were more likely to be encephalo-
pathic on admission, require renal replacement therapy or 
mechanical ventilation, and had higher mortality rates com-
pared with single time-point overdoses (37.3% vs. 27.8%; 
p = 0.025). These patients are at increased risk of develop-
ing multi-organ failure.
Table 2  Rate of gastrointestinal hospitalization among an elderly population-based cohort taking paracetamol, traditional NSAIDs, and PPIs
The rates of hospitalization for GI disorders (ulceration, perforation, or bleeding in the upper or lower GI tract) among elderly patients (≥65 
years) taking traditional NSAIDs or the combination of a traditional NSAID and paracetamol, with and without a PPI, are compared with the 
rate for paracetamol alone (≤ 3 g/day) in a Canadian population-based retrospective cohort study (N = 644,183)
Data compiled from Rahme et al. [36]
CI confidence interval, GI gastrointestinal, HR hazard ratio, NSAIDs non-steroidal anti-inflammatory drugs, PPIs proton pump inhibitors
Non-users of PPIs Users of PPIs
Drug exposure Upper/lower GI 
hospitalization
Drug exposure Upper/lower GI 
hospitalization
No. of prescriptions Total dura-
tion (years)
HR (95% CI) No. of prescriptions Total dura-
tion (years)
HR (95% CI)
Paracetamol ≤3 g/day 2,609,232 150,364 Reference (1.00) 1,032,269 58,344 0.95 (0.81–1.11)
Paracetamol ≥3 g/day 1,092,891 47,764 1.20 (1.03–1.40) 504,943 23,188 1.16 (0.94–1.43)
Paracetamol and NSAIDs 117,914 7858 2.55 (1.98–3.28) 40,800 2666 2.15 (1.35–3.40)
NSAIDs 1,463,323 91,379 1.63 (1.44–1.85) 315,238 19,839 1.07 (0.82–1.39)
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5  Conclusions
There is a rapidly increasing OA burden in an aging and 
increasingly overweight/obese society. Although paraceta-
mol is commonly used for analgesia in OA, the efficacy of 
paracetamol overall is poor and its use is driven by belief in 
its relative safety and by a lack of effective or tolerated alter-
native pharmacotherapies. Given that people with chronic 
pain may use paracetamol over many years, the only rel-
evant safety data derives from observational studies with 
their attendant problems, including selection bias (partici-
pants not randomly selected) and information bias (inac-
curate recording of OTC medications for example, some of 
which may be NSAIDs). Currently, this observational evi-
dence suggests an increased risk of AEs with paracetamol, 
although the data are difficult to interpret, and paracetamol 
remains safer than NSAIDs. Liver function abnormalities are 
not uncommon with paracetamol, and accidental overdose 
with supratherapeutic doses of paracetamol for pain is an 
important issue. The true risk of paracetamol use may be 
higher than is currently perceived in the clinical community. 
In this context, while the analgesic benefit of paracetamol 
in OA joint pain is uncertain, more careful consideration of 
its use is required.
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